Aristotle University Of Thessaloniki (AUTH)
Ο ρόλος της διαδερμικής χορήγησης τεστοστερόνης στη διέγερση των ωοθηκών σε γυναίκες με πτωχή ωοθηκική απάντηση που υποβάλλονται σε εξωσωματική γονιμοποίηση
Abstract
dc:descriptionPoor ovarian response remains one of the most challenging areas in reproductive medicine. Over the years, various stimulation protocols have been proposed for the management of poor responders, with controversial, however, results. Recently, it has been suggested that the accumulation of androgens in the micro milieu of the ovary, plays a critical role in early follicular development, granulosa cell proliferation and enhanced responsiveness of ovaries to follicle stimulating hormone (FSH). The aim of this randomized clinical trial (RCT) was to evaluate whether pre-treatment with transdermal testosterone increases the number of cumulus oocytes complexes (COCs) in poor responders undergoing intracytoplasmic sperm injection (ICSI) using recombinant gonadotrophins and gonadotrophin releasing hormone (GnRH) agonists. In addition, a systematic review and meta-analysis was performed aiming to evaluate testosterone pre-treatment on the probability of pregnancy achievement in poor responders undergoing ovarian stimulation for in-vitro fertilization (IVF). Fifty poor responders fulfilling the Bologna criteria were enrolled in this prospective, randomized, single blind, clinical trial. Patients have been randomized to either testosterone pre-treatment for 21 days (n=26) or no pre-treatment (n=24). All patients underwent a long follicular GnRHa protocol. Recombinant FSH stimulation was started on day 22 following GnRHa initiation. In the testosterone pre-treatment group, a daily dose of 10mg of testosterone gel was applied transdermally for 21 days starting from GnRHa initiation. No differences in baseline characteristics were observed between the two groups compared. The number of COCs retrieved was not different between the testosterone pre-treatment and the no pre-treatment groups. Similarly, no differences were observed regarding duration of FSH stimulation, fertilization rates and live birth rates per randomized patient between the two groups compared. Testosterone pre-treatment failed to increase the number of COCs as compared to no pre-treatment in poor responders undergoing ICSI. Regarding the systematic review and meta-analysis of all available published evidence, five eligible RCTs were identified evaluating testosterone pre-treatment in the form of transdermal (n=4) or oral (n=1) testosterone. The dose of transdermal testosterone ranged from 10-12.5mg for 15-21 days, while testosterone was given per os at a dose of 40mg/d for 48 days. Testosterone pre-treatment was associated with a significantly higher probability of clinical pregnancy and live birth. Currently, based on the limited available evidence, testosterone pre-treatment seems to increase clinical pregnancy and live birth rates in poor responders undergoing ovarian stimulation for IVF. However, further studies are necessary to increase our confidence to the currently available evidence as well as the precision of the estimates.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bosdou, Julia
- Μπόσδου, Ιουλία
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38968